tbuckley/cabot-search huggingface dataset:
End-of-life care for human immunodeficiency virus-infected patients with malignancies in Japan.
Authors: Yuki Kojima, Nami Iwasaki, Yuriko Yanaga, Junko Tanuma, Yusuke Koizumi, Tomoko Uehira, Mihoko Yotsumoto, Atsushi Ajisawa, Shotaro Hagiwara, Seiji Okada, Hirokazu Nagai
Journal: Journal of Clinical Oncology (2014)

e20501 Background: Human immunodeficiency virus (HIV) infection has become a chronic disease after the introduction of antiretroviral therapy (ARV), which has dramatically improved the survival of infected patients (pts). Therefore, common cancers frequently affecting the non-HIV population are now also being observed in HIV pts. This study aimed to clarify the actual status of end-of-life care provided to Japanese HIV pts with malignancies and to identify the difficulties encountered while providing end-of-life care to such pts in the palliative care unit (PCU). Methods: We performed a nationwide surveillance of end-of-life care provided to HIV pts with malignancies at regional center hospitals for HIV and at PCUs. We administered a questionnaire regarding the present status of end-of-life care provided and the difficulties encountered while providing care to end-stage cancer pts with HIV infection. Results: We sent questionnaires to all 378 regional center hospitals for HIV in Japan; 226 institutions (59.8%) responded. Fifty-five institutions (24.3%) provided palliative care to HIV pts with malignancies. Regarding the institution where pts received end-of-life care, 69.1% of pts were hospitalized at the each institution, whereas 18.2% of pts were transferred to PCUs. Among these 55 institutions, the requests of 16 (29.1%) were rejected that requested the transfer of these pts to PCUs. Further, all 285 PCUs in Japan received this questionnaire survey, and 179 PCUs (62.8%) responded. While thirteen PCUs (4.6%) provided care to hospitalized HIV pts with malignancies, twenty (11.2%) PCUs refused to accept these pts. The main reason for refusing these pts was the lack of experience and knowledge about HIV infection, especially regarding care for pts receiving ARV. Further, in 117 PCUs (65.4%), there was a criterion that pts receiving ARV will not be considered for hospitalization. Conclusions: Our findingssuggest that in Japan,HIV pts with malignancies, especially those receiving ARV, have difficulties in getting hospitalized at a PCU, probably owing to the lack of experience among the staff in treating such pts as well as the lack of knowledge about HIV. Thus, PCU staff should be educated about HIV infection.
Eliminating transportation barriers to outpatient radiation therapy for underserved patients with cancer.
Authors: Rene Eleanor Ashworth, Jennifer J. Wu, Richard F. Cohen, Yelena Novik
Journal: Journal of Clinical Oncology (2014)

e17569 Background: The cancer patients of Bellevue Hospital Center (BHC) and Woodhull Hospital (WH) represent and underserved community. Both hospitals belong to the Health and Hospital Corporation of New York City (NYCHHC) - a healthcare system that provides free transportation assistance for cancer patients with New York State Medicaid. BHC/WH cancer patients are referred to NYU Clinical Cancer Center (NYU CCC) for outpatient radiotherapy (RT); for these patients, commuting to NYU CCC poses a financial burden that hinders treatment compliance. As part of the NYU Cancer Institute research initiative on health disparities, $13,500 in grant funding was allocated towards providing this underserved population with the financial means to commute to the NYU CCC for outpatient RT. The purpose of this pilot study was to assess the impact of free metro-cards on the compliance rate of those BHC and WH cancer patients receiving outpatient RT at the NYU CCC. Methods: Eligible patients had a diagnosis of cancer and were referred from BHC or WH for outpatient RT; met New York state qualifications for Medicaid; did not live within 1 mile of NYU CCC; were able to use public transportation. Each patient was offered 1 free metro-card to cover the round-trip transportation expense of the initial RT consultation. Once the patient obtained a treatment schedule, additional metro-cards were provided to cover the transportation expense for the entire course of planned RT. Results: From 12/01/2012 until 12/12/2013, 177 patients from BHC and WH were eligible for this protocol; 103 were enrolled. The major ethnicity among enrolled patients was Hispanic, followed by Black and Asian. The average course of RT was 25 sessions. 102 patients completed their planned course of RT. 11/103 patients (10.7%) had at least 1 treatment delay, or missed RT session, solely attributed to unscheduled ED visits and/or hospitalizations; the average number of missed RT sessions was 8. 1 patient did not complete the planned treatment course due to intolerable RT-related adverse effects. The compliance rate was 70%. Conclusions: Eliminating the financial burden of transportation costs leads to significant improvement in compliance with scheduled RT in all patient groups.
Levels of plasma fibulin-3 and accuracy of identifying patients with malignant pleural mesothelioma.
Authors: Glen Reid, Michaela Kirschner, Mir Alireza Hoda, Michael Grusch, Steven Chuan-Hao Kao, Balazs Hegedus, Balazs Dome, Walter Berger, Walter Klepetko, Nico Van Zandwijk
Journal: Journal of Clinical Oncology (2014)

e18543 Background: Molecular markers for malignant pleural mesothelioma (MPM) are lacking, limiting early detection. Fibulin-3 was recently described as a highly sensitive and specific marker present in both plasma and pleural effusions from MPM patients. We sought to confirm this result in two independent sample series. Methods: Plasma samples from 63 MPM patients treated in Sydney (Royal Prince Alfred and Strathfield Private Hospitals) between 2010 and 2013, or Vienna (Medical University of Vienna) between 2011 and 2013 were included. Additional samples consisted of healthy individuals and patients with reactive pleuritis, other thoracic malignancies, or coronary artery disease collected over the same period. Blood samples were collected at the time of diagnosis for the various patients, were processed to plasma and stored at -80°C. Levels of fibulin-3 were measured using the Fibulin-3 ELISA kit (USCN Life Sciences) according to the manufacturer’s instructions. Statistical analyses were performed using SPSS21 (IBM). Results: Plasma fibulin-3 concentrations in samples from patients at both Institutes were 13.5 ± 1.5 ng/mL (n=63), compared with 10.6 ± 1.8 ng/mL in controls (n=45). This difference was not statistically significant (p=0.21). In the Sydney series, the mean fibulin-3 concentration in MPM patients was 15.4 ± 1.7 ng/ml (n=42) and 10.6 ± 1.8 ng/mL in controls (n=27). This difference did not reach statistical significance (p=0.07). Values in the Vienna series were 9.8 ± 2.7 ng/mL in MPM patients (n=21) and 10.6 ± 3.7 ng/mL in controls (n=18). These values are all within the range of those previously reported for plasma samples from asbestos-exposed but healthy individuals (13.9 ± 1.2 ng/mL), but do not reach the high levels reported for MPM patients (66.4 to 112.9 ng/mL). At a cut-off of 10.51 ng/mL, the sensitivity and specificity of fibulin-3 for discriminating MPM patients was 55.6 and 66.2 %, respectively. Conclusions: Our assessment of plasma fibulin-3 in two independent samples series suggests that fibulin-3 levels are neither specific nor sensitive enough to aid in the diagnostic process. Further studies are required to understand why these discrepancies in fibulin-3 levels in similar series exist.
Abstract 19690: Towards the Exhaustive Analysis of Left Ventricle Dysfunctions in Ischemic Cardiomyopathy: Integrating Mr-derived Wall Kinetics, Scar Transmurality and Fluid Dynamics
Authors: Silvia Pozzi, Filippo Piatti, Antonia Camporeale, Gabriella Di Giovine, Serenella Castelvecchio, Lorenzo Menicanti, Andreas Greiser, Emiliano Votta, Alberto C Redaelli, Massimo Lombardi
Journal: Circulation (2017)

Introduction: Post-ischemic dilated cardiomyopathy (DCM) is a complex clinical condition characterized by adverse left ventricular (LV) remodeling with impairment of systolic and diastolic function. Standard analyses of DCM include the assessment of LV function through CINE and late gadolinium enhancement (LGE) MRI. Only recently, 4D Flow was proposed to characterize LV function measuring in vivo 3D intraventricular flow. Hypothesis: Integrating CINE, LGE and 4D Flow analysis to comprehensively characterize the pathophysiology of post-ischemic DCM Methods: LV 3D geometry and volumes were obtained from CINE images. Location, extent and transmurality of scar tissue were quantified from LGE images (Fig.1a). LV hemodynamics were described from 4D Flow in terms of Wall Shear Stress (WSS) distribution on each of the 16 segments of the LV wall (Fig.1b) and diastolic vortices (Fig.1c).Study population included 19 patients (all males, age=66±10 years) with post-ischemic DCM and severe LV dysfunction (EF<35%). MRI ...
Effect of culturing of human adipose derived mesenchymal stem cells (ADSCs) under hypoxic conditions on production of wound healing cytokines and growth factors.
Authors: Dag Josefsen, Hans Petter Gullestad, Kirsti Solberg Landsverk, Grete Hasvold, Mohammad Reza Mirlashari, Gunnar Kvalheim
Journal: Journal of Clinical Oncology (2014)

e20723 Background: ADSCs are easily accessible in large quantities with a minimal invasive, safe and well-established surgical procedure. Usually, we obtain more than 300-500 times stem cells in 1 gram of fat compared to 1 gram of aspirated bone marrow. ADSCs are therefore an attractive cell source for tissue repair. Recently, we have initiated a phase I/II study in patients with chronic wounds following curative radiotherapy by injecting adipose stem cells into the wound area. Methods: Stromal Vascular Fraction (SVF) was isolated from liposuction cells during surgery using the CelutionTM system, and administered freshly back to the patient. Preliminary results from this study show that injection of SVF cells give complete healing of the lesions within 8 weeks. Normally, 200ml adipose tissue is harvested from the patient prior to SVF isolation. However, the number of SVF cells selected might become too little when larger chronic wounds need to be treated. Therefore, we are currently investigating the properties of ex vivo expanded ADSCs from SVF and their potential use in the treatment of chronic wounds. We, like others have shown that ADSCs do not propagate in vivo and the positive effect of ADSCs in tissue repair is through paracrine mechanisms. In this study we want to investigate the effects of hypoxia on the production of wound healing cytokines (IL-6, IL-8, and IL-10) and growth factors (VEGF and bFGF) by ADSCs. ADSCs were cultured under normoxia 21% O2 and hypoxia 1% O2 for 48h. Results: Hypoxia induced stabilization of hypoxia inducible factor 1 alpha (Hif-1 alpha) and affected secretion of wound healing growth factors and cytokines. In contrast, hypoxia did not affect the phenotype and morphology of ADSCs. Conclusions: Our finding support the strategy of incubation of ADSCs in hypoxia in order to induce increased secretion of wound healing cytokines and growth factors.
Clinical Feature and Genetic Alterations in Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia and Myeloid/NK Cell Acute Leukemia
Authors: Akira Nishimura, Kazuaki Yokoyama, Chika Yamagishi, Takuya Naruto, Tomohiro Morio, Akinori Kanai, Hirotaka Matsui, Naoko Higuchi, Akiko Takada, Haruna Okuno, Shoji Saito, Shuhei Karakawa, Shogo Kobayashi, Hideki Sano, Takashi Koike, Daisuke Hasegawa, Hiroyuki Fujisaki, Daiichiro Hasegawa, Kazutoshi Koike, Atsushi Ogawa, Akitoshi Kinoshita, Norio Shiba, Mizuka Miki, Hideki Nakayama, Yozo Nakazawa, Toshihiko Imamura, Takashi Taga, Souichi Adachi, Katsuyoshi Koh, Atsushi Manabe, Tomohiko Taki, Yasushi Ishida, Arinobu Tojo, Masatoshi Takagi
Journal: Blood (2018)
Estrogen receptor beta as a marker of tumor progression and prognosis in colorectal cancer.
Authors: Paulo Roberto Stevanato Filho, Samuel Aguiar, Maria D. Begnami, Fabio Oliveira Ferreira, Wilson Toshihiko Nakagawa, Ranyell Spencer Sobreira Batista, Celso Lopes Mello, Ademar Lopes
Journal: Journal of Clinical Oncology (2014)

e14605 Background: Familial Adenomatous Polyposis (FAP) is an disease characterized by the development of hundreds to thousands of adenomatous polyps in the colon and rectum, caused by germline mutations in the APC gene. These polyps arise in the second decade of life, during puberty, at peak production of sex steroids, which may suggest that they can act as a cofactor in the development of polyps and colorectal carcinogenesis linked to FAP. Conversely, the incidence of CRC is lower in women than men, and although the basis for this difference is unknown, sex steroids may be considered a contributing factor. Methods: This was a descriptive and analytical study in 120 patients at A.C. Camargo Cancer Center on the immunohistochemical expression of estrogen receptors α and β, progesterone and androgen in adenomatous polyps and in colorectal neoplasia both sporadic and originating from patients with FAP. Was analyzed the correlation between the interaction of expression of these hormone receptors with the carcinogenesis of CRC and its impact on overall prognosis. Results: The group with FAP polyps had lower expression than the group with sporadic polyps. With carcinogenesis, there was considerable loss of ER-beta expression of sporadic polyps, as 90% are strongly expressed and 100% have some degree of expression, when compared to the group with sporadic cancer, in which 80% developed with low or loss of ER-beta expression (p <0.001). With respect to TNM stage, there was a greater loss of ER-beta expression in the group with T3/T4 tumors when compared to T1/T2 group (p 0.015). Overall survival at 5 years of patients with CRC was 65.1% and association with ER-beta shows that individuals with loss of expression is related to lower overall survival at 5 years of 44.3% and 74.7% for patients absent of and in the presence of hormone expression, respectively (p 0.037). There was no significant expression of androgen receptors, progesterone and estrogen alpha between groups. Conclusions: The differences in intensity of ER-b expressionmay be a potential mechanism whereby estrogen changes the susceptibility to colon cancer and corroborates the possibility of estrogen to be a protective factor in the progression of colorectal carcinogenesis.
Abstract 13964: Effect of Coronary Sinus Ring Implantation on Reduction of Pulmonary Artery Systolic Pressure
Authors: Haytham S EL-Shurafa, Yahya AL-Hebaishi, Ali AL-Masood, Abdulrahman AL-Moghairi, Hussin AL-Amri, Abdullah AL-Khushail, Ahmed AL-Fagih
Journal: Circulation (2015)

Objectives: The purpose of paper is to report the mid-term(mean of 24 months) outcome of MV annuloplasty using Carillon coronary sinus (CS) Device therapy in reducing the pulmonary artery systolic pressure(PASP) at PSCC, Saudi Arabia. Background: Carillon CS Device is one of the devices used for treatment of severe functional symptomatic mitral regurgitation in heart failure patients, which is associated with high mortality and difficulty in controlling heart failure symptoms. This study provides a snapshot of the real-world clinical demographic data and outcome on reducing the PASP in a single center using this treatment modality. Methods: A total of 30 patients with severe symptomatic mitral valve regurgitation (MR) underwent Carillon CS Device therapy at Prince Sultan Cardiac Center. All patients were in New York Heart Association functional class III or IV, and 82% of patients had an ejection fraction ≤25%. Results: The Carillon CS Device implant rate was 80%. A total of 1 patient (3%) died within 30 days after the procedure. The mean Intensive care unit and hospital length of stay was 3 days. None of the patients required mitral valve surgery after the MV ring device implant procedure. There was significant drop in the PASP , compared to base line seen (from 60.4±11.9 to 43.0±13.3 (p&lt;0.009)) . 85% of patients had New York Heart Association functional class II or class I, at a mean follow up of 18 months .Six-minutes-walk-test improved 193± 7 m, to 470±5 m (p&lt;0.002). Conclusions: Carillon CS Device therapy used in high risk severe functional symptomatic MR is promising with a low rate of hospital mortality and significant improvement of symptoms and PASP .
Efferocytosis Fuels Requirements of Fatty Acid Oxidation and the Electron Transport Chain to Polarize Macrophages for Tissue Repair
Authors: Shuang Zhang, Samuel Weinberg, Matthew DeBerge, Anastasiia Gainullina, Matthew Schipma, Jason M. Kinchen, Issam Ben-Sahra, David R. Gius, Laurent Yvan-Charvet, Navdeep S. Chandel, Paul T. Schumacker, Edward B. Thorp
Journal: Cell Metabolism (2018)
Somatic activating mutations in <i>PIK3CA</i> cause generalized lymphatic anomaly
Authors: Lara Rodriguez-Laguna, Noelia Agra, Kristina Ibañez, Gloria Oliva-Molina, Gema Gordo, Noor Khurana, Devon Hominick, María Beato, Isabel Colmenero, Gonzalo Herranz, Juan M. Torres Canizalez, Rebeca Rodríguez Pena, Elena Vallespín, Rubén Martín-Arenas, Ángela del Pozo, Cristina Villaverde, Ana Bustamante, Carmen Ayuso, Pablo Lapunzina, Juan C. Lopez-Gutierrez, Michael T. Dellinger, Victor Martinez-Glez
Journal: The Journal of Experimental Medicine (2018)

Generalized lymphatic anomaly (GLA) is a vascular disorder characterized by diffuse or multifocal lymphatic malformations (LMs). The etiology of GLA is poorly understood. We identified four distinct somatic PIK3CA variants (Glu542Lys, Gln546Lys, His1047Arg, and His1047Leu) in tissue samples from five out of nine patients with GLA. These same PIK3CA variants occur in PIK3CA-related overgrowth spectrum and cause hyperactivation of the PI3K-AKT-mTOR pathway. We found that the mTOR inhibitor, rapamycin, prevented lymphatic hyperplasia and dysfunction in mice that expressed an active form of PIK3CA (His1047Arg) in their lymphatics. We also found that rapamycin reduced pain in patients with GLA. In conclusion, we report that somatic activating PIK3CA mutations can cause GLA, and we provide preclinical and clinical evidence to support the use of rapamycin for the treatment of this disabling and deadly disease.
Changes in items of a comprehensive geriatric assessment (CGA) during follow-up: Results from the IN-GHO registry.
Authors: Friedemann Honecker, Carsten Bokemeyer, Gerd Kallischnigg, Susanne Huschens, Ulrich Wedding
Journal: Journal of Clinical Oncology (2014)

9547 Background: Elderly cancer patients (pts) are a heterogenous population. A CGA helps to describe the heterogeneity in a structured way, and can help to detect changes occurring during cancer therapy. The internet based IN-GHO registry prospectively collected data of elderly cancer pts from >100 centres in Germany and Austria, both at baseline, and during follow-up within 6 months. Methods: Demographic data, data on activities of daily living (ADL), instrumental activities of daily living (IADL), Karnofsky-Performance-Statuts (KPS), comorbidity (Charlson score), number of co-medication, mobility (Timed-Up&Go), cognition (Mini-Mental State Examination), and depression (2-question screening SCID) were collected at baseline. ADL, IADL, and KPS were documented again within 8-12 weeks after baseline. Differences of 5 or more points in ADL, 1 or more points in IADL, and 10% or more in KPS were classified as changes. Data from 3,168 pts aged 70+ years were documented, and changes in items of CGA were analyzed by McNemar test to compare the number of pts with increased and decreased scores. Results: Mean age was 76 years, 23.9% were > 80 years. 52.7% were female, 77.9% were treated as outpatients, 73.5% had a solid tumor, and 26.5% had a hematological neoplasia. At baseline, ADL was <100 in 37.6% (data from 3,113 pts), IADL was <8 in 46.6% (data from 3,133 pts), and KPS was <80% in 23.5% (data from 2,771 pts). During follow-up, the following changes were observed: ADL score decreased in 23.0% and increased in 13.4% (p<0.001; data from 2,261pts), IADL score decreased in 29.8% and increased in 11.8% (p<0.001; data from 2,266 pts), and KPS score decreased in 35.5% and increased in 17.7% (p<0.001; data from 1,999 pts). Most frequently observed changes affected the items climbing stairs in ADL, and housekeeping in IADL, respectively. Conclusions: In ADL, IADL, and KPS, significant changes were observed in elderly cancer pts during follow-up. Highest frequency of changes was observed in KPS. While the majority of changes signified deterioration, a minority of pts showed improvement, indicating a beneficial effect of therapy.
Cost/outcome and relative values of anticancer drugs in metastatic and refractory colorectal cancer.
Authors: Helmy M. Guirgis
Journal: Journal of Clinical Oncology (2014)

e14500 Background: High costs of anticancer drugs limited affordability and utilization.The objective was to study the cost/outcome of drugs in 1st-, 2nd-line and refractory metastatic colorectal cancer (mCRC). Methods: Estimated 3-6 month-costs of evaluated drugs were divided by reported median overall survival gain over control in days (OSg). Results were expressed as cost/life-year gained (LYG). Assuming $50,000 threshold, relative values (RV) were calculated as 50,000/cost/LYG. Drugs in 1st- demonstrated lower cost/outcome and higher RV than later lines. Cost of one added survival day by regorafenib was $671 with 0.21 RV (Table). Out of pocket 20% monthly co-payments of bevacizumab, aflibercept, and regorafenib were $864, $1,133 and $1,880 respectively. Conclusions: There is a trend for cost/outcome of drugs to increase and RV to decrease from 1st-line to refractory mCRC. Cost/outcome was negatively impacted by extending treatment. Cost/outcome of regrafenib seemed relatively high. Heterogeneity of disease and population preclude fair comparison. Drugs OSg (days) Cost US$ Cost /OSg Cost /LYG RV Cetuximab iv weekly (w) x 12 w, 1st-line, wild KRAS 141 27,408 194 69,978 0.71 IFL + bevacizumab iv,1st-line x 6 cycles (5.0mg/Kg q 2w) x 12, maintenance 141 12,960 25,920 92 184 33,089 66,179 1.51 0.75 Bevacizumab x 6 cycles + additional costs, post-progression 42 14,460 344 123,943 0.40 Aflibercept iv + FOLFIRI + additional costs x 3 months x 6, 2nd-line 48 17,000 34,000 354 708 127,500 255,000 0.39 0.20 Regorafenib po, x 3 months, x 6, refractory 42 28,200 56,400 671 1,342 241.714 483,429 0.21 0.10
Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial
Authors: Christiane Querfeld, John Thompson, Matthew H. Taylor, Raju Pillai, Lisa DS Johnson, Tina Catalano, Penka S. Petrova, Theresa Thompson, Robert A. Uger, Yaping Shou, Oleg E. Akilov
Journal: Blood (2018)
Kinetic Catalytic Inhibition and Cell-Based Analysis, Not Just Target Binding, Are Required to Assess Kinase Selectivity of Covalent Inhibitors: Comparable BTK vs TEC Selectivity Profile for Ibrutinib and Acalabrutinib
Authors: Melissa Hopper, Tarikere Gururaja, Taisei Kinoshita, James P. Dean, Ronald Hill, Ann Mongan
Journal: Blood (2018)
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
Authors: Nicholas J Short, Elias J. Jabbour, Farhad Ravandi, Xuelin Huang, Nitin Jain, Koji Sasaki, Naveen Pemmaraju, Naval G. Daver, Joseph David Khoury, Jeffrey L. Jorgensen, Yesid Alvarado, Marina Y. Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia, Musa Yilmaz, Gautam Borthakur, Jan A. Burger, Steven M. Kornblau, William G. Wierda, Courtney D. DiNardo, Alessandra Ferrajoli, Patrice Nasnas, Jovitta Jacob, Rebecca E. Garris, Susan M. O'Brien, Hagop M. Kantarjian
Journal: Blood (2018)